Research and Development

We are dedicated to advancing plant-based medicines through rigorous scientific research. Under the direction of our esteemed COO Bernard Pieters, we are pursuing medicinal cannabis and psilocybin research to develop effective therapies amid a global shift in attitudes towards natural medicines as sound, safe alternatives to addictive opioids.

Unlocking the Potential of Psilocybin

Medical psychedelic research has undergone a renaissance in recent years. Psilocybin is a naturally occurring compound found in certain mushrooms that is structurally similar to the human neurotransmitter serotonin, which regulates mood and perception.

Early clinical trials show when administered in controlled settings with psychological support, psilocybin may be a safe and effective treatment for mental health disorders like depression, PTSD, and anxiety. With over 20 years leading cannabis innovations, Bernard is now spearheading efforts to streamline commercial psilocybin cultivation and extraction for medicinal use.

Establishing Cannabis as a Trusted Treatment

Additionally, our cannabis R&D is focused on developing new strains and applications for rare cannabinoids that are tailored to meet the needs of patients and researchers developing therapies for a variety of chronic conditions. By breeding innovative strains with tailored cannabinoid and terpene profiles, we can provide the raw materials for customised cannabis therapies targeting specific symptoms and diseases.

Driving Progress Through Research

Our vision is a future where psilocybin and cannabis are trusted treatment options. Under Bernard’s leadership, we aim to establish rigorous evidence supporting these plant medicines as safe, effective therapies for those suffering.